Loading...
•
Dec 31, 2025
Pediatrix Q4 2025 Earnings Report
Pediatrix Medical Group reported its fourth quarter 2025 earnings, with net revenue of $493.8 million and diluted EPS of $0.40.
Key Takeaways
Pediatrix Medical Group reported fourth quarter 2025 results that were in line with revised upward expectations, showing solid same-unit revenue growth despite an increase in variable practice incentive compensation. The company achieved net revenue of $493.8 million, net income of $33.7 million, and Adjusted EPS of $0.50.
Net revenue for Q4 2025 was $493.8 million, a decrease from $502.4 million in the prior-year period, primarily due to non-same unit activity.
Diluted EPS for Q4 2025 was $0.40, an increase from $0.36 in Q4 2024.
Adjusted EBITDA for Q4 2025 was $65.8 million, compared to $68.7 million in the prior-year period, mainly due to higher same-unit expense.
Same-unit net revenue grew by 4.0 percent, driven by improvements in collection activity, favorable payor mix, and higher patient acuity.
Forward Guidance
Pediatrix anticipates its 2026 Adjusted EBITDA to be in the range of $280 million to $300 million.
Positive Outlook
- Anticipated Adjusted EBITDA range of $280 million to $300 million for 2026.
- Continued focus on strong future positioning.
- Commitment to coordinated, compassionate, and clinically excellent services.
- Significant investments in research, education, quality-improvement, and safety initiatives.
- Growth strategy for hospital-based and maternal fetal businesses.
Challenges Ahead
- Facing healthcare industry headwinds.
- Potential impacts of legal, regulatory, political, and macroeconomic developments.
- Uncertainty over the future of Medicaid and state budgetary constraints.
- Impact of surprise billing legislation.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...